Apollo Hospitals Enterprise Limited · NSE:APOLLOHOSP
Apollo Hospitals Enterprise — Merger or Acquisition (June 2025)
17 slides from Apollo Hospitals Enterprise's merger presentation, Jun 30, 2025
Slide 1: Apollo Healthco Ltd - Composite Scheme of Arrangement
Apollo Healthco Ltd India’s Largest Omnichannel pharmacy distribution and Digital health platform Composite Scheme of Arrangement June 30, 2025
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor an
Slide 3: Executive Summary
Executive Summary • Announced an INR 2,475 Cr (US $300mn) investment from Advent in April 2024 and our intent to consolidate Keimed (in stages) into Apollo HealthCo Ltd (AHL). Obtained Board approval and subsequent shareholder approval Transaction in August 2024 for Advent Investment and Keimed merg
Slide 4: Executive Summary (2/2)
Executive Summary (2/2) • All regulatory and other approvals as necessary for the proposed structure would be obtained over the next few Approval months process and • Independent valuation conducted by KPMG (BSR) and BDO, and fairness opinion provided by Axis Capital Governance • Shareholder approva
Slide 5: Proposed Scheme - Process
Proposed Scheme - Process • Proposes to undertake below transactions sequentially, via a scheme of arrangement, subject to requisite corporate and regulatory approvals • Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform Step 1 (shares of AHEL in Apollo Healthco Ltd
Slide 6: Composite scheme : Overview
Composite scheme : Overview Shareholder approved Resultant Group Structure Resultant Group Structure Proposed Now in August 2024 (Post all approvals) • Automatic listing of New Co • Direct participation of AHEL shareholders in New Co Keimed AHEL promoters and Other SH 15% + 2.5%** AHEL Keimed 56.7%
Slide 7: Strategic Rationale for Proposed Structure (1/2)
Strategic Rationale for Proposed Structure (1/2) Creates India’s largest listed Omni channel Pharmacy (OCP) distribution and Digital health platform with a scale of INR ~ 25k Cr (~US$3 bn) in Revenues by end FY27 • Enables AHEL shareholders to gain direct shareholding to India’s largest omni channel
Slide 8: Strategic Rationale for Proposed Structure (2/2)
Strategic Rationale for Proposed Structure (2/2) • AHEL will continue to hold ~ 15% of New co directly (17.5% including interest held through FHPL) - Establishes an independent, focused yet Integrated healthcare platform offering curated solutions, spanning across entire patient journey. - Allows AH
Slide 9: Capabilities
India’s largest Omnichannel Pharmacy and Digital Health powerhouse….…. FY25 Key Operational Metrics ~US$2 bn 150mn+ ~65mn+ Scale Proforma Combined Revenue Life time customers Annual customers Largest omni channel healthcare company Industry leading customer life time value 6,626 75k+ 3k+ 19-min 19,0
Slide 10: Deep Offline and Online presence
…………with deep Offline and Online presence Offline Pharmacy Distribution Apollo 24|7 India’s largest Organized Pharmacy Platform with A full-suite digital platform with a one-stop presence in ~1,200 cities/ towns spread across 22 integrated access covering entire patient journey States and 5 union te
Slide 11: Keimed | India's Largest Pharma Distributor
Keimed | India’s Largest Pharma Distributor Keimed has >2x the scale of its nearest competitor in a highly fragmented industry with 70,000+ distributors Unmatched Trusted High Quality Preferred Sales State-of-the-art Experienced Scale and Manufacturer Customer Base Partner Infrastructure Management
Slide 12: Combined Financial Metrics | Snapshot
Combined Financial Metrics | Snapshot FY25 figures in INR Cr Online + Offline Telehealth AHL Keimed2,3 NewCo4 GMV: 3,077 GMV: 11,091 GMV: 18,196 Revenue 8,014 12,554 Revenue: 1,149 Revenue: 9,163 Revenue: 16,267 EBITDA1 612 143 756 406 1,155 Post Ind AS Margin % 7.6% 12.5% 8.2% 3.2% 7.1% 24/7 operat
Slide 13: Balance Sheet position – Mar'25 | Stronger post the transaction
Balance Sheet position – Mar’25 | Stronger post the transaction As of 31 March 25, AHL1 Keimed2 New Co3 Figures in INR Cr Net Worth 2,3214 1,143 3,425 Net Debt / (Cash) 383 1,551 1,934 Other liabilities 200 82 283 Sources of Funds 2,904 2,776 5,642 Net Working Capital 1,628 2,296 3,925 Other assets
Slide 14: Merged Entity | Financial Outlook (Proforma)
Merged Entity | Financial Outlook (Proforma) FY27 Exit FY25 Run-rate Target Target to achieve EBITDA breakeven for digital business in next 4 quarters GMV: 18,196 Cr GMV: ~28,000Cr Revenue Proposed integration to enable higher Revenue: 16,267 Cr Revenue: ~25,000 Cr margin realisation through supply
Slide 15: Transaction Advisors
Transaction Advisors Financial advisors - VedaCorp Legal advisors for the scheme - Shardul Amarchand Mangaldas & Co (SAM) Fairness Opinion provided by Axis Capital Independent valuation conducted by KPMG (BSR) and BDO 15
Slide 16: Steps and Timelines
Steps and Timelines Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 Oct-26 Nov-26 Dec-26 Jan-27 Feb-27 Mar-27 Board meeting to approve the Scheme Submission of application with stock exchanges/SEBI Submission of application to NOC from
Slide 17: Thank You.
Thank You.
Apollo Hospitals Enterprise — Merger or Acquisition (June 2025) on 6ix